(Q27851573)

English

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (English)

1 reference

13 November 2016

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Andrea Sartore-Bianchi

24

0 references

Alberto Bardelli

22

0 references

Salvatore Siena

23

0 references

Diether Lambrechts

35

0 references

Frédérique Penault-Llorca

11

object named as

Frédérique Penault-Llorca

0 references

37

object named as

Sabine Tejpar

0 references

Jef De Schutter

4

object named as

Jef De Schutter

0 references

Eric Van Cutsem

33

object named as

Eric Van Cutsem

0 references

Pierre Laurent-Puig

10

object named as

Pierre Laurent-Puig

0 references

Hubert Piessevaux

34

object named as

Hubert Piessevaux

0 references

object named as

Miriam Martini

21

0 references

Camilla Qvortrup

object named as

Camilla Qvortrup

31

0 references

Federico Cappuzzo

object named as

Federico Cappuzzo

16

0 references

object named as

Per Pfeiffer

30

0 references

object named as

Bruno Vincenzi

13

0 references

Giuseppe Tonini

object named as

Giuseppe Tonini

15

0 references

Daniele Santini

object named as

Daniele Santini

14

0 references

Fortunato Ciardiello

object named as

Fortunato Ciardiello

29

0 references

Josep Tabernero Caturla

object named as

Josep Tabernero

25

0 references

George Fountzilas

6

object named as

George Fountzilas

0 references

Hubert Piessevaux

1 reference

ORCID Public Data File 2021

David Bernasconi

object named as

David Bernasconi

3

1 reference

ORCID Public Data File 2021

author name string

Wendy De Roock

1

0 references

Bart Claes

2

0 references

Bart Biesmans

5

0 references

Konstantine T Kalogeras

7

0 references

Vassiliki Kotoula

8

0 references

Demetris Papamichael

9

0 references

Philippe Rougier

12

0 references

Milo Frattini

17

0 references

Francesca Molinari

18

0 references

Piercarlo Saletti

19

0 references

Sara De Dosso

20

0 references

Teresa Macarulla

26

0 references

Frédéric Di Fiore

27

0 references

Alice Oden Gangloff

28

0 references

Tine Plato Hansen

32

0 references

Mauro Delorenzi

36

0 references

language of work or name

1 reference

based on heuristic

inferred from title

publication date

August 2010

0 references

Lancet Oncology Commission

0 references

11

0 references

753-62

0 references

8

0 references

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Unbiased Recursive Partitioning: A Conditional Inference Framework

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970130-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70130-3

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_4lqfbzowxrc2tgt27t5qmikwhe

1 reference

https://api.fatcat.wiki/v0/release/4lqfbzowxrc2tgt27t5qmikwhe

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851573&oldid=1843833632"